This CME activity from ASCO 2012 reviews continuous androgen deprivation for hormone-sensitive metastatic prostate cancer in men with minimal disease spread.
This fact sheet helps multiple myeloma learn more about treatment options and how to cope with prognosis, symptoms, causes.
A phase 3 trial presented at ASCO showed FAC plus weekly paclitaxel was associated with a slight but clinically relevant improvement in DFS vs FAC alone.
Taxane-based chemotherapy combined with lapatinib results in shorter PFS than with trastuzumab in patients with HER2+ metastatic breast cancer.
Patients with HER2+ locally advanced or metastatic breast cancer experience improved survival with T-DM1.
Several sub-analyses at ASCO 2012 confirmed the efficacy of Everolimus plus exemestane in postmenopausal women with advanced breast cancer.
This fact sheets helps patients to offer care and support systems with cancer caregivers.
Palliative care, concurrent with standard oncological care, should be considered early in the course of illness for any patient with metastatic cancer or high symptom burden.
Administration, safety, and efficacy are similar in both agents. However, the frequency of administration makes a significant difference for patients.
The 2011-2012 ASCO standards for the safe administration of chemotherapeutic agents have been released.
